Advances in the Treatment of Stage III Non-Small Cell Lung Cancer Webinar

Friday, August 8, 2025, 12:00 PM - 1:00 PM EST, Online


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

This free webinar, featuring a panel discussion with Michigan Medicine faculty from hematology and oncology, radiation oncology, pulmonary and critical care medicine, and thoracic surgery, will provide an update on the evolving landscape of non-small cell lung cancer (NSCLC) treatment. The panel will explore the critical role of invasive staging in NSCLC, key patient- and disease-specific factors to consider when determining treatment, and recent clinical trial updates on neoadjuvant, adjuvant, and perioperative immunotherapy for stage III NSCLC.

1. Summarize the role and clinical significance of invasive staging in the diagnosis of non-small cell lung cancer (NSCLC).
2. Apply patient-specific and disease-specific factors that should be considered when deciding between surgery and radiation treatments.
3. Assess recent clinical trial data on neoadjuvant, adjuvant, and perioperative immunotherapy for stage III NSCLC.

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Accessibility Statement

The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.

Questions? Please contact [email protected].

Mitigation of Relevant Financial Relationships

The University of Michigan Medical School adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners, or others are required to disclose all relevant financial relationships with ineligible entities. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Friday, August 8, 2025